Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ICMT | O60725 | 3/20 | 0.38 |
| ▸ | NT5E | P21589 | 4/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240197 | 0.77 | CYP1A2 (0.49) | COMTALDH1A1KDM4ENPC1LMNA | |
| SCHEMBL3926262 | 0.77 | NPC1 (0.56) | COMTALDH1A1KDM4ENPC1LMNA | |
| SCHEMBL18000570 | 0.74 | PTGS1 (0.31) | — | |
| SCHEMBL15950989 | 0.71 | COMT (0.60) | COMTALDH1A1KDM4ENPC1LMNA | |
| SCHEMBL30268376 | 0.70 | CYP2A6 (0.58) | COMTALDH1A1KDM4ENPC1LMNA | |
| SCHEMBL13537099 | 0.70 | CYP2A6 (0.58) | COMTALDH1A1KDM4ENPC1LMNA | |
| SCHEMBL3611446 | 0.70 | ALDH1A1 (0.49) | ALDH1A1KDM4ENPC1LMNASMN1; SMN2 | |
| SCHEMBL13035808 | 0.69 | NT5E (0.50) | COMTALDH1A1KDM4ENPC1LMNA | |
| SCHEMBL8807138 | 0.69 | ICMT (0.56) | ICMTNT5EUSP30CTSVCTSL | |
| SCHEMBL332532 | 0.69 | ALDH1A1 (0.39) | COMTALDH1A1KDM4ENPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292281-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | REATA PHARMACEUTICALS, INC. (US) | 2021-09-23 | — | — | US | claimed |
| CN-112654610-A | Pyrazole and imidazole compounds for inhibiting IL-17 and ROR gamma | 里亚塔医药公司 | 2021-04-13 | — | — | CN | claimed |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2016-09-15 | — | — | US | claimed |
| EP-2985281-A2 | ISOINDOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Celgene Corporation (US) | 2016-02-17 | — | — | EP | claimed |
| CN-104744434-A | ISOINDOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | CELGENE CORP | 2015-07-01 | — | — | CN | claimed |
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2013-07-18 | — | — | US | claimed |
| EP-2593425-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | Agios Pharmaceuticals, Inc. (US) | 2013-05-22 | — | — | EP | claimed |
| US-20130045976-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CELGENE CORPORATION (US) | 2013-02-21 | — | — | US | claimed |
| WO-2012009678-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | WO | claimed |
| CN-102264720-A | Isoindoline compounds for the treatment of cancer | — | 2011-11-30 | — | — | CN | claimed |
| EP-2358697-A1 | Isoindoline compounds for use in the treatment of cancer | CELGENE CORPORATION (US) | 2011-08-24 | — | — | EP | claimed |
| WO-2010053732-A1 | ISOINDOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | CELGENE CORPORATION (US) | 2010-05-14 | — | — | WO | claimed |
| EP-3925609-A1 | METHODS OF TREATING MULTIPLE MYELOMA WITH IMMUNOMODULATORY COMPOUNDS IN COMBINATION WITH ANTIBODIES | Celgene Corporation (US) | 2021-12-22 | — | — | EP | disclosed |
| US-20210147380-A1 | CYSTEINE-DEPENDENT INVERSE AGONISTS OF NUCLEAR RECEPTORS ROR-GAMMA/ROR-GAMMA-T AND METHODS OF TREATING DISEASES OR DISORDERS THEREWITH | REATA PHARMACEUTICALS, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| CN-112654610-A | Pyrazole and imidazole compounds for inhibiting IL-17 and ROR gamma | 里亚塔医药公司 | 2021-04-13 | — | — | CN | disclosed |
| US-20200113896-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARM LLC (US) | 2020-04-16 | — | — | US | disclosed |
| CN-101421264-A | Is suitable for treating serotonin 5HT6Heterocyclic compounds for receptor-modulated responsive disorders | ABBOTT GMBH & CO KG (DE) | 2009-04-29 | — | — | CN | disclosed |
| EP-2029528-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007118900-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007118899-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200113896-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | MTOR, ULK1, RICTOR | COMT 3410/4885ALDH1A1 4213/4885KDM4E 1585/4885 |
| US-20210147380-A1 | CYSTEINE-DEPENDENT INVERSE AGONISTS OF NUCLEAR RECEPTORS ROR-GAMMA/ROR-GAMMA-T AND METHODS OF TREATING DISEASES OR DISORDERS THEREWITH | RORC, RORA, RORB | COMT 1132/4885ALDH1A1 818/4885KDM4E 3465/4885 |
| US-20130045976-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CPT1A, CYP11B2, NPC1 | COMT 69/4885ALDH1A1 674/4885KDM4E 4053/4885 |
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | COMT 1284/4885ALDH1A1 597/4885KDM4E 669/4885 |
| US-20210292281-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | RORC, RORB, RORA | COMT 4280/4885ALDH1A1 672/4885KDM4E 3221/4885 |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | COMT 1284/4885ALDH1A1 597/4885KDM4E 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.